Table of Contents Table of Contents
Previous Page  153 / 398 Next Page
Information
Show Menu
Previous Page 153 / 398 Next Page
Page Background

148

sclerosis, presence or absence of subperiosteal bone formation,

sequestra, the visibility of the mandibular canal, cortical border

were scored. Differences between outcomes of denosumab-related

osteonecrosis (DRONJ) of the jaw and BRONJ patients were stud-

ied.

Findings:

In denosumab cases predominantly sclerosis was seen.

Bisphosphonates more sclerosis depending on the duration of the

use or the potency of the bisphosphonates. Sequestra were rare

with denosumab necrosis compared to bisphosphonate necrosis.

Subperiosteal bone formation was predominantly seen in patients

using bisphosphonates. Prominent lamina dura, the visibility of the

mandibular canal and cortical border were seen in both denosumab

and bisphosphonates.

Conclusions:

This study shows a difference in radiological

aspects between denosumab and bisphosphonate cases. In deno-

sumab a sclerosis is seen which is visible only in long-term

bisphosphonate cases. Sequestra were rare in denosumab. These

effects are possibly caused by a difference in the remaining func-

tioning amount of osteoclasts. Further research is mandatory.

http://dx.doi.org/10.1016/j.ijom.2017.02.510

Surgical treatment of a cohort of 150 patients with stage

II/III medication-related osteonecrosis of the jaw

S.E.C. Pichardo

∗

, J.P.R. van Merkesteyn

Leiden University Medical Center, The Netherlands

Background:

A side effect of antiresorptive medication

such as bisphosphonates and denosumab is medication-related

osteonecrosis of the jaw (MRONJ). This can be difficult to treat.

Objectives:

The aim of this study was to evaluate the surgical

treatment protocol used in our hospital for MRONJ patients. The

patients were analysed and followed at the Leiden University

Medical Center.

Methods:

150 patients who were seen with therapy-resistant

MRONJ between 2003 and 2016 were analysed. Clinical features,

medical and dental history, antiresorptive use, and the use of other

medications were recorded. The thorough surgical intervention

was combined with antimicrobial treatment and only performed

by senior surgeons, following the principles of our previously

reported protocol.

Findings:

125 patients were surgically treated and followed for

6–105 months with a mean of 18 months. The surgical approach

was successful in 92% of the patients.

Conclusion:

More than 90% of the patients were cured with our

surgical protocol. We conclude that this combined antimicrobial

and surgical treatment protocol has a high success rate in all stages

of MRONJ.

http://dx.doi.org/10.1016/j.ijom.2017.02.511

Study on outcomes of oral squamous cell carcinoma after

treatment for two years follow-up at Bangabandhu Sheikh

Mujib Medical University

M.S. Rahman

∗

, A.F.M.S. Rahman

Bangabandhu Sheikh Mujib Medical University, Dhaka,

Bangladesh

Objective:

To evaluate the treatment outcome of oral squamous

cell carcinoma patients by routine follow-up visit and by this

efficacy of institutional management.

Methods:

In the study 56 patients, aged 26–75 years treated

at BSMMU for squamous cell carcinoma of oral cavity were

included. Patients were treated by different modality such

as surgery with incomplete/delayed/no radiotherapy (32.14%),

surgery with radiotherapy (53.57%), surgery with concomi-

tant radiochemotherapy (10.71%) and neoadjuvant therapy then

surgery and adjuvant therapy (3.57%). By routine follow-up,

suspected new tumour growth was determined and fine-needle

aspiration cytology and histopathologywas done. Residual tumour

growth, local recurrence, lymph node metastasis and second pri-

mary tumour growth were detected and by this overall outcome

measured.

Results:

The majority of patients were female and the male to

female ratio was 1:1.4. Tumours of different sites of oral cavity

were treated of which stage I, 23.21%; stage II, 62.5%; stage III,

14.21%; and stage IV patients were not included. Overall out-

come of treatment was 50.0% for two years follow-up. Residual

tumour growth was 9.09%, local recurrence was 36.36%, lymph

nodemetastasis was 2.27%and second primary tumour was 2.27%

within two years. Outcome for two years in stage I 100%, in stage

II 43.3% and in stage III 28.5%. Statistical analysis with SPSS

version 10 showed

P

value for one-year follow-up.

Conclusion:

Our results suggest that to evaluate the treatment

outcome routine follow-up is necessary. Also efficacy and failure

of treatment can be measured.

http://dx.doi.org/10.1016/j.ijom.2017.02.512

Bisphosphonate-related osteonecrosis of the jaws: our

experience in up to 120 cases

C.E.X.S. Ribeiro da Silva

∗

, A.C. Rodriguez, D.M. Costa,

M. Martins, V. Oliveira, R. Murad Neto

Instituto de Ensino, Pesquisa e Difusão Prevent Senior, Brazil

Osteonecrosis of the jaw has been related to the use of bisphospho-

nates for more than a decade, with numerous attempts of different

treatments and even the presentation protocols by surgeons asso-

ciations. We aim to present a series of clinical cases with various

complexities, presenting forms of treatment adopted by our ser-

vice. We collected clinical data from 120 patients, considering

the type of bisphosphonate treatment, time of use, location and

extent of osteonecrosis and the treatment performed in our hos-

pital. We have adopted the protocol to perform surgical removal

of necrosis, associated with pentoxifylline and tocopherol, and

hyperbaric chamber therapy for indicated cases. We resumed the

treatment of overall shape necrosis in 90%of cases, and significant

improvement of signs and symptoms in 10%. We conclude that

the combined use of surgery to other therapies may be indicated